Using radiofrequency ablation to treat liver cancer by targeting sympathetic nerves
Official title: Intravascular Radiofrequency Ablation of Sympathetic Nerves for the Treatment of Hepatocellular Carcinoma
Run by Zhongda Hospital · NCT06694636 · Data updated 2026-11-12
This study is testing a new treatment for advanced liver cancer that combines a special heat procedure with surgery to target nerves, to see if it helps patients who haven't responded to other therapies.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 25 Years to 75 Years |
| Sex | All |
| Enrollment | 5 (estimated) |
| Sponsor | Zhongda Hospital Academic / other |
| Locations | 1 site (Nanjing, Jiangsu) |
| Status | Recruiting |
| Started | February 1, 2024 |
| Main results expected | February 1, 2026 |
| Study ends | February 1, 2026 |
| Registry record updated | November 19, 2024 |
| Trial ID | NCT06694636 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are patients with clinically or pathologically confirmed hepatocellular carcinoma that is locally progressed or metastatic and unresectable.
✕Probably not a fit
Patients who are not suitable for ablation surgery or have other significant health issues may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This clinical trial involves patients with hepatocellular carcinoma (HCC) who are treated with endovascular radiofrequency ablation combined with desympathetic nerve surgery. The approach aims to assess the safety and efficacy of this treatment method in patients with advanced, unresectable HCC who have progressed after second-line therapy. Following the procedure, patients will undergo regular follow-up evaluations, including blood tests and imaging studies, to monitor their condition and treatment response.
Why it matters
Potential benefit: If successful, this treatment could provide a new therapeutic option for patients with advanced liver cancer who have limited treatment choices.
How similar studies have gone: While this approach is innovative, similar studies using radiofrequency ablation for liver cancer have shown promising results, suggesting potential for success.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Clinically or pathologically confirmed hepatocellular carcinoma (HCC) * Locally progressed or distant metastatic unresectable advanced HCC * Progressed after second-line therapy * Agree to participate in the study and sign the informed consent form Exclusion Criteria: * Not suitable for ablation surgery * Pregnant, lactating and planning to become pregnant * Orthostatic hypotension * Mixed liver cancer * Intestinal obstruction * Obvious bleeding tendencies and hematologic diseases * Acute or severe systemic infection; * Stroke or transient ischemic attack (TIA) within two weeks; * Acute coronary syndrome within two weeks; * Evaluated to be not suitable for this trial by investigators
Where it's running
-
Zhongda Hospital
Nanjing, Jiangsu, China Recruiting
Study contacts
- Principal investigator: Gao-Jun Gao-Jun — Zhongda Hospital
- Study coordinator: Hai-Dong Zhu
- Email: zhuhaidong9509@163.com
- Phone: +86-25-83272121
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
InstaSure Non-Invasive Finger-Press Test for HCC
This study tests a non-invasive finger-skin test to help identify hepatocellular carcinoma in adults.
-
BGB-B2033 vs Sorafenib or Lenvatinib for advanced liver cancer
This study tests whether the investigational drug BGB-B2033 can help people with advanced hepatocellular carcinoma when given after prior PD-1/PD-L1 therapy, compared with the standard medicines sorafenib or lenvatinib.
-
Zinc add-on with targeted therapy plus immunotherapy for advanced liver cancer
This study tests whether adding daily zinc to standard targeted therapy and immunotherapy helps people with unresectable or advanced hepatocellular carcinoma.
-
68Ga-SorB PET/CT imaging for solid tumors
This study tests a new PET tracer called 68Ga-SorB to see if it can safely and accurately detect tumors in adults with melanoma, liver, lung, breast, pancreatic, ovarian cancer, or cholangiocarcinoma.
-
Hepatocellular Carcinoma Patient Registry (CHARM Hepatocellular Carcinoma MEA)
This observational study collects medical records of adults with hepatocellular carcinoma to understand how the disease presents and progresses across regions in the Middle East and North Africa.
-
GLP-1 RA plus standard treatment in first-line metastatic GI cancers
This early-phase trial tests whether adding a GLP-1 receptor agonist to standard first-line chemotherapy is safe and feasible for people with metastatic pancreatic, colorectal, or liver cancer.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.